AngioDynamics initiates the AMBITION BTK RCT and registry to advance treatment for patients with chronic limb-threatening ischemia and below-the-knee peripheral artery disease.

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options ...

Persistent over-dilation of muscle microvasculature may be one cause of chronic limb-threatening ischemia, recent studies by ...

UK King’s Daughters became the first hospital in Kentucky — and the only hospital in the region — to offer a new minimally invasive procedure for ...

Normothermic machine perfusion (NMP) to preserve livers prior to transplant was associated with significantly improved ...

AngioDynamics, Inc. announced the commencement of the AMBITION BTK multicenter randomized controlled trial (RCT), which will ...

Intramuscular fat, contained within muscle tissue, increases the risk of serious heart disease, regardless of other risk ...

AngioDynamics (ANGO) announced the start of a randomized study of the Auryon Atherectomy System used in combination with Standard Balloon ...

Brain injury resulting from hypoxia (oxygen deprivation) or ischemia (restricted blood flow) represents a major challenge in medical research and clinical ...

Innovative muscle patches derived from stem cells demonstrate efficacy in heart repair, improving function in primates and a ...